Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KC1036 in adolescents with advanced Ewing sarcoma
CTR20242898Phase 2Active
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of connitinib in Ewing sarcoma, sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jan 2025; status: active.
02
Drugs
connitinib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on CTR20242898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242898.